stockrowANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00.
- EPS
- −14.3%
- Free cash flow
- −17.1%
Quarter to July 2026, against a year earlier
Follow ANIX
Alert me
ANIXA BIOSCIENCES INC (ANIX) EV/Sales
As of 6 November 2026, ANIXA BIOSCIENCES INC (ANIX) trades at a EV/Sales of 101×. Over the past ten years it has ranged from 0.6× (March 2015) to 211× (April 2023); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 80.1× | (46.26%) |
| FY2021 | 149× | 172.40% |
| FY2019 | 54.7× | 15.09% |
| FY2018 | 47.5× | 64.18% |
| FY2017 | 28.9× | (77.77%) |
| FY2016 | 130× | 5,248.02% |
| FY2015 | 2.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Apr 2023 | 103× | (30.58%) |
| Oct 2021 | 149× | 79.87% |
| Jan 2021 | 82.8× | 42.99% |
| Apr 2019 | 57.9× | 21.90% |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −66.1× |
| NBP NovaBridge Biosciences compare | −5.3× |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | 0.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ANIX ANIXA BIOSCIENCES INC | 101× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)